LBT Innovations Limited

Equities

LBT

AU000000LBT8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 06:55:21 22/05/2024 BST			5-day change	1st Jan Change
0.018 ^AUD	+5.88%		+5.88%	+63.64%

05-08	Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024
04-29	LBT Innovations Sells APAS Independence Instrument to NovaCina	MT

LBT Innovations : Company Presentation at AusBiotech 2021

October 26, 2021 at 06:16 am

26 October 2021

Australia Biotech Invest & Partnering 2021 conference

On Tuesday 26 October our CEO and Managing Director, Brent Barnes presented at the Australia Biotech Invest & Partnering 2021 conference.

This conference is AusBiotech's leading investment conference providing investors with the opportunity to hear from industry leaders about new technology and trends in the life sciences industry.

If you missed the presentation a recording is available below.

Attachments

Original document
Permalink

Disclaimer

LBT Innovations Ltd. published this content on 26 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2021 05:15:05 UTC.

Latest news about LBT Innovations Limited

Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024	05-08
LBT Innovations Sells APAS Independence Instrument to NovaCina	04-29	MT
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data	03-13	MT
LBT Innovations' APAS PharmaQC Completes Primary Validation; Shares Up 79%	03-13	MT
Transcript : LBT Innovations Limited, Q2 2024 Earnings Call, Feb 29, 2024	02-28
LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher	02-23	MT
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-22	CI
LBT Innovations Makes First Sale of APAS PharmaQC; Shares Jump 31%	02-22	MT
LBT Innovations Limited Appoints Dan Hill as Non-Executive Director	12-13	CI
LBT Innovations Limited Announces Retirement of Damian Lismore as Director. Effective 29 November 2023	11-26	CI
LBT Innovations Secures Approval for AU$1.7 Million Loan Restructuring	11-06	MT
LBT Innovations Fully Repays Share Placement Facility	13/10/23	MT
LBT Innovations Raising Up to AU$4.5 Million Via Entitlement Offer; Shares Down 27%	13/10/23	MT
LBT Innovations Secures R&D Tax Refund for Fiscal Year 2023; Shares Rally 11%	05/09/23	MT
LBT Innovations Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
LBT Innovations Flags AU$13 Million Impairment Charge	04/08/23	MT
LBT Innovations Limited Appoints Rebecca Wilson as Director	05/07/23	CI
LBT Innovations Appoints Chair; Shares Jump 7%	03/07/23	MT
LBT Innovations Limited Announces the Retirement of Simon Arkell as Non-Executive Director	30/03/23	CI
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23	CI
Transcript : LBT Innovations Limited, Q2 2023 Earnings Call, Jan 25, 2023	24/01/23
LBT Innovations, AstraZeneca Partner to Develop APAS Pharma Product	09/01/23	MT
Astrazeneca Partners LBT for Apas Pharma Development	08/01/23	CI
LBT Innovations Limited Receives an Initial Purchase Order from Thermo Fisher Scientific, Inc	19/12/22	CI
LBT Innovations Subsidiary Appoints Thermo Fisher as Exclusive Distributor for Europe	19/12/22	MT

Chart LBT Innovations Limited

Duration

Period

More charts

Company Profile

LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LBT INNOVATIONS LIMITED	+63.64%	15.19M
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+43.57%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research